1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Caplin Point Laboratories Limited

Caplin Point Laboratories Limited

CAPLIPOINT.NS
Caplin Point Laboratories LimitedIN flagNational Stock Exchange of India
1,972.90
INR
-15.20
- -
149.96BMarket Cap
Caplin Point Laboratories Limited
CAPLIPOINT.NS
(National Stock Exchange of India)

Recent

price

1,972.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
10.69
14.19
16.81
22.91
33.32
- -
51.65
69.53
83.71
111.65
138.58
167.69
191.72
221.18
254.94
287.74
261.65
Revenue per Share
0.83
1.06
1.85
3.42
5.43
- -
12.65
19.16
23.35
28.42
32.03
39.61
49.62
60.19
70.57
84.36
74.35
Basic EPS, GAAP
0.98
1.52
-1.78
1.76
3.23
- -
5.56
8.8
11.03
5.91
35.51
44.48
10.27
22.73
56.89
68.83
- -
Free Cash Flow per Basic Share
- -
- -
- -
0.58
0.96
- -
0.84
1.5
2
4.3
0.4
3
4
4.5
5
6
- -
Dividend per Share
3.07
3.55
4.62
6.63
10.26
16.36
28.18
45.83
67.16
91.18
122.89
159.36
205.06
260.47
2
2
- -
Book Value per Share
3.85
4.45
5.69
8.11
12.24
17.88
29.62
47.88
78.7
115.93
148.26
198.03
250.05
307.41
377.76
470.58
- -
Tangible Book Value per Share
76
76
76
76
76
76
76
76
76
76
76
76
76
76
76
76
76
Basic Weighted Avg Shares
808
1,072
1,270
1,731
2,518
- -
3,902
5,256
6,329
8,445
10,483
12,694
14,538
16,796
19,375
21,872
19,887
Sales/Revenue/Turnover
8.46
9.03
16.06
19.3
21.16
- -
28.69
33.56
32.98
27.15
27.98
27.4
27.4
29.65
29.99
31.46
30.5
Operating Margin (%)
23
12
15
35
84
- -
133
190
234
316
370
469
450
534
660
728
663
Depreciation Expense
63
80
140
258
410
- -
956
1,448
1,766
2,150
2,423
2,998
3,763
4,571
5,363
6,412
5,651
Net Income, GAAP
23.26
28.13
36.67
27.34
22.97
- -
21.04
23.22
22.18
20.18
19.83
20.05
16.48
18.25
20.05
19.07
19.8
Effective Tax Rate (%)
7.78
7.47
11.01
14.93
16.3
- -
24.5
27.55
27.9
25.46
23.11
23.62
25.88
27.21
27.68
29.32
28.42
Profit Margin (%)
141
-155
-443
-590
-431
-1
659
1,954
4,076
6,782
8,717
10,901
12,842
15,621
18,276
21,997
- -
Working Capital
97
16
35
21
9
7
5
3
3
13
5
12
9
9
29
21
- -
LT Debt
291
336
432
619
935
1,357
2,251
3,639
6,330
9,566
12,034
15,099
19,073
23,468
28,864
36,308
- -
Total Equity
12.47
15.69
29.64
43.82
51.8
- -
48.63
45.88
32.56
22.47
21.22
20.34
19.43
19.11
17.73
17.06
- -
Return on Invested Capital (%)
17.13
20.99
39.15
56.83
62.73
- -
56.38
51.69
39.63
31.74
25.32
25.66
26.66
25.2
51.47
1,053.04
1,061.44
Return on Capital (%)
28.94
31.99
45.27
60.78
64.31
- -
56.81
51.78
41.34
35.91
29.92
28.08
27.25
25.88
53.82
4,218.68
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
21
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
29
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
76
- -
Market Capitalization
189,997
151,972
160,955

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
21,340
- -
Cash, Cash Equivalents & STI
- -
5,108
- -
Accounts Receivable, Net
- -
6,325
- -
Inventories
- -
3,361
- -
Total Current Liabilities
- -
3,064
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
21
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
40.2%
24.72%
25.79%
Free Cash Flow
- -
48.32%
21.01%
Net Income, GAAP
- -
21.53%
19.57%
Sales/Revenue/Turnover
- -
15.88%
12.89%
Total Cash Common Dividend
- -
145.28%
20.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,953
4,101
4,355
4,359
16,796
2025
4,590
4,831
4,930
5,024
19,375
2026
5,102
5,428
6,002
- -
21,872

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13.62
15.13
15.44
- -
60.19
2025
16.32
17.22
18.28
18.75
70.57
2026
20.1
21.56
22.38
- -
84.36

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
4.5
2025
- -
- -
- -
- -
5
2026
- -
- -
- -
- -
6
Similar Companies
Can B Corp. (CANB)
Emerald Health Therapeutics, Inc. (EMHTF)
Vetoquinol S.A. (0O1O.L)
Nanexa AB (publ) (NANEXA.ST)
Shandong Wohua Pharmaceutical Co., Ltd. (002107.SZ)
Solara Active Pharma Sciences Limited (SOLARA.BO)
Business
Caplin Point Laboratories Limited manufactures and markets a broad portfolio of pharmaceutical formulations, including liquid and lyophilized vials, pre-filled syringes, ophthalmic droppers, pre-mix bags, tablets, dry syrups, softgels, capsules, suppositories, liquid syrups, emulsion injections, topicals, and sachets; the company serves regulated markets such as the US and EU as well as emerging markets in Latin America, Francophone Africa, the Caribbean, Southeast Asia, and beyond, with over 4,000 product licenses across 36 therapeutic segments covering more than 65% of the WHO essential drug list. Founded in 1990 and headquartered in Chennai, India, with manufacturing facilities in Puducherry, Gummidipoondi, Visakhapatnam, and near Chennai, as well as subsidiaries including Caplin Steriles Limited, Caplin Point Far East Ltd, and various Latin American entities, Caplin Point operates a fully integrated model emphasizing generics, branded generics, injectables, ophthalmics, softgels, and oncology products for hospitals, wholesalers, retail, and institutional customers targeting the bottom of the pyramid. Recent developments include the June 2025 acquisition of Triwin Pharma S.A. DE C.V. in Mexico by subsidiary Caplin Point Far East to enable government tenders and a stock-and-sale model; the acquisition of Neoethicals Chile SpA; USFDA approval for Brimonidine-Timolol ophthalmic solution by Caplin Steriles in February 2025; launches of the first RTU bag, ophthalmic emulsion, and injectable emulsion products; filing of 30+ products in Mexico with 13 approvals and a 60+ pipeline; first insulin approval in Central America; establishment of private market sales via an owned warehouse in Chile; over 30 planned US product launches in FY26 via Caplin Steriles USA Inc., which has achieved $2.5 million revenue since inception; ongoing capex of over Rs 1,000 crore nearing completion for expanded capacities in lyophilized injectables, dual-chamber syringes, oncology API, and backward integration via API plants in Visakhapatnam and Thervoy; and plans to file GLP-1 products, biosimilars, and first DMFs in emerging and regulated markets.